X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

Content Team by Content Team
8th February 2019
in Drug Development, Manufacturing, News, Packaging & Logistic
Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Solentim, a global leader in cell line development instrumentation, and bioengineering company ATUM announced a technology partnering and collaboration agreement. This agreement creates the most efficient cell line development solution for biotherapeutic drug developers yet, by integrating Solentim’s VIPS™ (verified in-situ plate seeding) hardware for isolating single cells with ATUM’s efficient Leap-In Transposase® expression technology.

“This collaboration allows Solentim and ATUM to offer a unique integrated solution to our customers and significantly accelerate stable cell line development workflows,” explains Dr Ian Taylor, Commercial Director of Solentim. “This approach means that scientists no longer need to pre-screen for high producing clones, e.g. using fluorescence detection to measure secretion from single cells or colonies. Instead, using the Leap-In Transposase technology, almost every transfected cell is a high producing clone. Combining this with high seeding efficiencies from VIPS has huge practical benefits to the workflow in time, cost and efficiency.”

“The protein pharmaceutical market is approaching a quarter of a trillion USD per year. Establishing and isolating the most suitable cell lines producing these drugs is a major manufacturing bottleneck. We are extremely excited to combine our advanced bioengineering tools with the leading instrumentation technology of Solentim to accelerate the discovery and development process” says Dr. Jeremy Minshull, CEO of ATUM.

About VIPS
VIPS™ from Solentim is a unique all-in-one instrument which performs single cell seeding into 96 well plates, verifying success by z-stack imaging the nanolitre (nL) volume droplets, and then performing whole well imaging of the single cell for the assurance of clonality regulatory requirements.

About Leap-In Transposase Technology
The Leap-In Transposase® rapidly catalyzes the stable integration of genes into a target genome. Genes are integrated as multiple independent copies with structural integrity perfectly maintained. This greatly reduces the screening burden required compared with slower, more traditional “random integration” methods where the introduced DNA is randomly fragmented and often rearranged. ATUM’s Leap-In technology is protected by over a dozen pending and issued patents.

About Solentim
Solentim enables its life science industry customers to develop a greater number of more effective pharmaceuticals to help patients live healthier, for longer. We do this through designing and manufacturing highly innovative instruments that facilitate the process of commercial cell line development. This phase of biopharmaceutical production is a high-value process which is intrinsically expensive and time-consuming. Our solutions significantly shorten the upstream cell line development workflow process and therefore make drug production faster and more cost effective. Our products, Cell Metric® and VIPS™, represent the next generation of single cell printing and provide documented proof of monoclonality for the FDA and other regulatory bodies. All of the world’s top ten pharmaceutical companies use Solentim products. Established in 2010 and with global headquarters in Dorset, UK; the organisation employs over 40 people across the UK, Europe, Asia and the USA.

About ATUM
ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fuelling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster.

Previous Post

IQVIA Launches IQVIA Biotech, Dedicated to Emerging Biotech and Biopharma Industry

Next Post

US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
Next Post
US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In